Center For Technology Commercialization

Novel Target for Treating Pulmonary Fibrosis

(CHMC Ref. Id: 2009-1209)

Overview:

An inhibitor has been identified that provides a novel pharmacological strategy for treating pulmonary fibrosis.  Administration of this compound to a transgenic mouse model of pulmonary fibrosis resulted in significantly reduced lung proliferation and matrix gene expression (Collagens I, III and Elastin) compared to untreated mice.  These findings support the possibility that the inhibitor could be a useful therapeutic for treating pulmonary fibrosis.

Applications:

• Treatment of pulmonary fibrosis

Advantages:

• Provides an opportunity to treat an unmet medical need, as treatment options for pulmonary fibrosis are limited.

Patent Information:

• Patent Applications Pending

Cincinnati Children's Lead Inventor:

William D. Hardie, M.D.